Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials
about
sameAs
Antiplatelet therapy in acute coronary syndromes: focus on ticagrelorPlatelet glycoprotein IIb/IIIa receptor blockade in coronary artery diseaseClosed headpiece of integrin IIb 3 and its complex with an IIb 3-specific antagonist that does not induce openingStable Coordination of the Inhibitory Ca2+ Ion at the Metal Ion-Dependent Adhesion Site in Integrin CD11b/CD18 by an Antibody-Derived Ligand Aspartate: Implications for Integrin Regulation and Structure-Based Drug DesignStructure-Guided Design of a High-Affinity Platelet Integrin IIb 3 Receptor Antagonist That Disrupts Mg2+ Binding to the MIDASThe role of antiplatelet therapy in the management of acute coronary syndromesHaemostaseologyPreventable stroke and stroke preventionComplications of oral antiplatelet medicationsCommon variations in platelet glycoproteins: pharmacogenomic implicationsAntiplatelet treatment in unstable angina: aspirin, clopidogrel, glycoprotein IIb/IIIa antagonist, or all three?Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteersClopidogrel in acute coronary heart diseaseDrug treatment of peripheral arterial disease in the elderlyRebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO TrialRole of abciximab in the treatment of coronary artery diseaseDrug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trialCurrent developments in anti-platelet therapyClinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic diseasePlatelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO studyDual pathway therapy in acute coronary syndrome.Small molecule agonists of integrin CD11b/CD18 do not induce global conformational changes and are significantly better than activating antibodies in reducing vascular injury.The Role of Glycoprotein IIb/IIIa Inhibitors- A Promise Not Kept?Dissolution of arterial platelet thrombi in vivo with a bifunctional platelet GPIIIa49-66 ligand which specifically targets the platelet thrombusTriple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis.Targeting integrin and integrin signaling in treating thrombosis.The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus IntracoronaryDissolution of pre-existing platelet thrombus by synergistic administration of low concentrations of bifunctional antibodies against β3 integrin.Rising like the phoenix?Monitoring of platelet function in the setting of glycoprotein IIb/IIIa inhibitor therapy.Optimizing glycoprotein IIb/IIIa inhibition: lessons from recent randomized controlled trials.Integrin targeted therapeutics.Critical review of unstable angina and non-ST elevation myocardial infarctionBeta3 integrin deficiency promotes atherosclerosis and pulmonary inflammation in high-fat-fed, hyperlipidemic mice.Oral platelet glycoprotein IIb/IIIa receptor inhibitors--part II.Novel agents for anti-platelet therapy.Secondary stroke prevention: review of clinical trials.The antithrombotic potential of selective blockade of talin-dependent integrin alpha IIb beta 3 (platelet GPIIb-IIIa) activation.Peripheral arterial disease of the lower extremities.Tirofiban in acute coronary syndromes.
P2860
Q24605508-78E73B52-228A-4161-A98A-2411A77CF6D5Q24793321-1C3DCEB3-020C-4A4A-9754-4F4A1A427E59Q27663824-807ACDC0-2D18-4AD1-952A-1E9A35E97927Q27675632-C0C7B462-0353-4C9A-A11B-C16A6CDAF59BQ27678064-31254EE1-C924-43B2-8D16-046C48277BFCQ28176548-6D734192-889A-4F73-BE92-A86911BF7972Q28182273-AC003763-B366-460F-A1AE-DAFE951A5E01Q28187602-1032C765-C351-4B45-B11D-53E0BFB4912AQ28187982-1DFEF2D2-C1E2-4C43-9FF0-CEF0960575D7Q28191774-09391A6A-7AB3-4035-BF17-DC4A531E3B6CQ28193219-1DB924C7-B7E2-4CCC-B85B-D8D243763C54Q28193315-005990DD-59AE-4D8D-84BD-4E54B3FD37A4Q28193776-03E811BA-D3CB-40D5-BF9B-1628BAEE3397Q28195312-7C8A556C-F033-4AE3-8BF4-0651494C18DCQ28199563-831878C3-8E39-4C6F-A805-9170DFC40A61Q28200177-31964AAA-29DB-4207-88FD-19EDD8859333Q28200573-6651B64B-574F-4432-9AAB-D96D9ACFD465Q28200685-5387D1A4-FC7C-42E3-85DB-982FCD125114Q28218124-17A6472B-7FE8-4428-ABB3-6B1EFC4CC762Q28218790-E321C01C-CDEC-42C1-9211-38586C778662Q30252011-A42E016B-08D5-45D0-8F49-547EE31CE57AQ30578431-3B0C4D9C-9228-4230-9D73-68B10097FA57Q33387192-94386CD4-6B40-4AD1-A2FF-9D307476FA81Q33389941-89E9A0B4-6DBA-4F31-8E58-60EFD7AFBA51Q33390176-991E1140-810B-41EB-990D-C4579E5A289DQ33417854-49D4F63D-15BC-4A26-8A97-796B1161C034Q33572281-56D72272-3F37-4586-A906-10C607BF091DQ34064897-C9AD0280-D801-416D-BB82-D3666F0E9349Q34347772-9FAACD62-DCC5-49B1-B186-8CD111CFEEDCQ34675287-1A6E55A7-5CF7-41E4-BC37-3E05884E68C2Q34712338-C4FAD841-C91F-48D6-9821-6234B71D70FFQ34912684-A405EE0F-209F-4920-8905-79B0597EE3A7Q35037630-3CC3137F-F3B6-40FA-8BAE-6758D7A22732Q35144122-6D4613B0-78D6-4294-8489-3F587499DA0EQ35549715-93153499-2E7A-4449-B8D6-1BB5697FDDB4Q35574825-C1E859C5-DA17-4E47-94C7-5A8181165055Q35799749-A316297C-BF7D-49BC-A795-5678EFB5C909Q35868825-31D7B8ED-68AC-4DC1-8FA4-4E98A7FCCBF3Q35990502-A62B3588-4146-4418-AC26-57995CFA9980Q36107187-CE25F923-CDFD-4AAC-9388-1C87D0DCC22C
P2860
Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Increased mortality with oral ...... multicenter randomized trials
@ast
Increased mortality with oral ...... multicenter randomized trials
@en
Increased mortality with oral ...... multicenter randomized trials
@nl
type
label
Increased mortality with oral ...... multicenter randomized trials
@ast
Increased mortality with oral ...... multicenter randomized trials
@en
Increased mortality with oral ...... multicenter randomized trials
@nl
prefLabel
Increased mortality with oral ...... multicenter randomized trials
@ast
Increased mortality with oral ...... multicenter randomized trials
@en
Increased mortality with oral ...... multicenter randomized trials
@nl
P2093
P921
P356
P1433
P1476
Increased mortality with oral ...... multicenter randomized trials
@en
P2093
P356
10.1161/01.CIR.103.2.201
P407
P50
P577
2001-01-16T00:00:00Z